SBC Medical Group (NASDAQ:SBC) Stock Gets Price Target Increase from BTIG Research

SBC Medical Group (NASDAQ:SBC – Get Free Report) had its price target hoisted by equities research analysts at BTIG Research from $8.00 to $10.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s target price suggests a potential upside of 36.05% from the company’s previous close.

Several other equities analysts have also issued reports on SBC. Weiss Ratings upgraded SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 9th. Wall Street Zen downgraded SBC Medical Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

View Our Latest Report on SBC Medical Group

SBC Medical Group Stock Performance

NASDAQ:SBC opened at $7.35 on Friday. The firm’s 50-day moving average is $5.13 and its 200-day moving average is $3.98. SBC Medical Group has a 52-week low of $2.78 and a 52-week high of $7.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. The company has a market cap of $755.93 million, a price-to-earnings ratio of 14.70, a PEG ratio of 3.30 and a beta of 0.52.

SBC Medical Group (NASDAQ:SBC – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.03. SBC Medical Group had a net margin of 27.26% and a return on equity of 19.14%. The business had revenue of $58.58 million during the quarter, compared to analyst estimates of $48.90 million. Equities research analysts anticipate that SBC Medical Group will post 0.44 earnings per share for the current year.

Hedge Funds Weigh In On SBC Medical Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Williams & Novak LLC lifted its stake in SBC Medical Group by 31.2% during the second quarter. Williams & Novak LLC now owns 18,686 shares of the company’s stock worth $58,000 after purchasing an additional 4,449 shares during the period. Nisa Investment Advisors LLC bought a new stake in shares of SBC Medical Group in the 3rd quarter valued at approximately $36,000. Williams & Novak Wealth Management LLC grew its stake in shares of SBC Medical Group by 40.9% in the 3rd quarter. Williams & Novak Wealth Management LLC now owns 26,330 shares of the company’s stock valued at $130,000 after purchasing an additional 7,644 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of SBC Medical Group in the 1st quarter worth approximately $43,000. Finally, Bank of America Corp DE acquired a new position in shares of SBC Medical Group in the 2nd quarter worth approximately $35,000. 60.82% of the stock is owned by institutional investors.

About SBC Medical Group

(Get Free Report)

SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.

Further Reading

Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.